Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections.
- Resource Type
- Article
- Authors
- Dunne, Michael W; Aronin, Steven I; Das, Anita F; Gupta, Jayanti; Akinapelli, Karthik; Breen, Jeanne; Zelasky, Michael T; Puttagunta, Sailaja
- Source
- Clinical Infectious Diseases. 6/15/2023, Vol. 76 Issue 12, p2213-2215. 3p.
- Subject
- *URINARY tract infections
*ANTI-infective agents
*DISEASE complications
- Language
- ISSN
- 1058-4838
The article examines the use of a desirability of outcome ranking (DOOR) end point in a study comparing sulopenem and ertapenem for treating complicated urinary tract infections (cUTIs). While sulopenem was not as effective as ertapenem based on overall success rates, both treatments showed high clinical success rates. The inclusion of asymptomatic bacteriuria (ASB) as a primary end point is questioned due to its limited impact on patient well-being.